Biopharmaceutical company TFF Pharmaceuticals Inc (NASDAQ:TFFP) reported on Thursday that the last subject in the multiple ascending dose (MAD) portion of its Phase 1 clinical trial of Voriconazole Inhalation Powder has completed their last clinic visit, following repeated dosing.

Voriconazole Inhalation Powder is a next-generation, direct-to-lung, inhaled dry powder version of Voriconazole, an antifungal drug for treating Invasive Pulmonary Aspergillosis (IPA). In the trial, repeated doses of up to 80mg/dose twice daily for seven days in healthy volunteers were well tolerated.

The single ascending dose (SAD) and MAD phases, with 32 participants in each stage, were conducted to evaluate the safety, tolerability and pharmacokinetic profile of Voriconazole Inhalation Powder.

TFF Pharmaceuticals' proprietary Thin Film Freezing (TFF) technology platform allows the reformulation of Voriconazole into dry powder particles to directly target the site of the fungal infection in the lung.